Adolescent Mite Allergy Safety Evaluation
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 250
Summary
- Conditions
- Allergic Rhinitis
- Allergic Rhinoconjunctivitis
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: single-armedMasking: None (Open Label)Masking Description: Non applicablePrimary Purpose: Treatment
Participation Requirements
- Age
- Between 12 years and 17 years
- Gender
- Both males and females
Description
This trial is a 28-day, single-arm open-label phase III trial to evaluate safety of the house dust mite SLIT-tablet in adolescents (12-17 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma. Approximately 250 adolescents will be enrolled in the trial and will receive ...
This trial is a 28-day, single-arm open-label phase III trial to evaluate safety of the house dust mite SLIT-tablet in adolescents (12-17 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma. Approximately 250 adolescents will be enrolled in the trial and will receive the house dust mite SLIT tablet. The trial is conducted in several European countries.
Tracking Information
- NCT #
- NCT04541004
- Collaborators
- Syneos Health
- Investigators
- Principal Investigator: Andreas Horn, MD HNO Praxis am Neckar
Get Well Soon